Changes in cytokine profile during local IL-2 therapy in cancer patients

被引:0
|
作者
Tomova, R
Pomakov, J
Jacobs, JJL
Adjarov, D
Popova, S
Altankova, I
Den Otter, W
Krastev, Z
机构
[1] Univ Hosp St Ivan Rilski, Gastrointestinal Clin, Sofia 1431, Bulgaria
[2] Univ Hosp St Ivan Rilski, Dept Clin Immunol, Sofia 1431, Bulgaria
[3] Univ Hosp St Ivan Rilski, Dept Clin Lab, Sofia 1431, Bulgaria
[4] Univ Utrecht, Fac Vet Med, Dept Pathobiol, NL-3508 TD Utrecht, Netherlands
关键词
IL-2; therapy; cytokines; IL-5; IL-10;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Exogenous interleukin 2 (IL-2) can influence the complex cytokine network in vivo. This study investigated the cytokine profile of patients with different malignancies before and after local IL-2 administration. Patients and Methods: The human TH1 / TH2 cytometric bead array (CBA) kit was used to investigate IL-2, IFN gamma, TNF alpha. IL-4, IL-5 and IL- 10 in a control group and in 13 patients. Results: The baseline serum IL-4 levels in patients were lower than in healthy controls, while the baseline ascitic IL-10 levels in patients was higher than in serum. The IL-2 applications induced a strong serum increase in IL-2 and IL-5 and even more in ascites, while IL-10 increased weakly and mainly locally. One month after the start of therapy, the serum IFN gamma had increased in patients, reaching the level of the control group. Conclusion: After local injection, IL-2 probably leaks into the blood circulation. The higher increases of IL-2, IL-5 and IL-10 in ascites compared to the serum suggests that the injected cytokines and their effects are mainly local. The minor increase of the immunosuppressive IL-10 could explain the therapeutic difference between local and systemic IL-2 therapy since IL-10 levels markedly increase after systemic IL-2 therapy. IL-5 was always increased after IL-2 therapy and, consequently, may be a downstream mediator of antitumour responses.
引用
收藏
页码:2037 / 2047
页数:11
相关论文
共 50 条
  • [31] A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
    Quijano-Rubio, Alfredo
    Bhuiyan, Aladdin M.
    Yang, Huilin
    Leung, Isabel
    Bello, Elisa
    Ali, Lestat R.
    Zhangxu, Kevin
    Perkins, Jilliane
    Chun, Jung-Ho
    Wang, Wentao
    Lajoie, Marc J.
    Ravichandran, Rashmi
    Kuo, Yun-Huai
    Dougan, Stephanie K.
    Riddell, Stanley R.
    Spangler, Jamie B.
    Dougan, Michael
    Silva, Daniel-Adriano
    Baker, David
    NATURE BIOTECHNOLOGY, 2023, 41 (04) : 532 - +
  • [32] DEPRESSED PMNC BLASTOGENIC RESPONSE IN PATIENTS WITH CANCER OF THE HEAD AND NECK - A STUDY OF IL-2 PRODUCTION, IL-2 CONSUMPTION, AND IL-2 RECEPTOR EXPRESSION
    ESKINAZI, DP
    PERNA, JJ
    ERSHOW, AG
    MIHAIL, RC
    LARYNGOSCOPE, 1989, 99 (02): : 151 - 157
  • [33] USE OF IL-2 GENE-TRANSFER IN LOCAL IMMUNOTHERAPY OF CANCER
    BUBENIK, J
    LOTZOVA, E
    INDROVA, M
    SIMOVA, J
    JANDLOVA, T
    BUBENIKOVA, D
    CANCER LETTERS, 1992, 62 (03) : 257 - 262
  • [34] THE ROLE OF LYMPHOKINES IN THE CANCER-RELATED IMMUNE-DEFICIENCY - INVITRO RESPONSE TO IL-2, PRODUCTION OF IL-2 AND IL-2 RECEPTOR EXPRESSION IN PATIENTS WITH ADVANCED CANCER
    MANTOVANI, G
    COIANA, A
    MASSIDDA, A
    PROTO, E
    MANDUCO, D
    FLORIS, C
    MACCIO, A
    PUSCEDDU, G
    DELGIACCO, GS
    IMMUNOBIOLOGY, 1987, 175 (1-2) : 97 - 98
  • [35] Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2
    T. J. P. Spoormakers
    W. R. Klein
    J. J. L. Jacobs
    Th. S. G. A. M. Van Den Ingh
    J. W. Koten
    W. Den Otter
    Cancer Immunology, Immunotherapy, 2003, 52 : 179 - 184
  • [36] Comparison of immunological changes between subcutaneous and intravenous route of administration of IL-2 in cancer patients
    Nouri, AME
    Lowdell, M
    Entazami, Z
    Tezabwala, BU
    Goode, A
    Oliver, RTD
    UROLOGIA INTERNATIONALIS, 1996, 56 (01) : 1 - 5
  • [37] THE DEVELOPMENT OF ANTI-INTERLEUKIN-2 (IL-2) ANTIBODIES IN CANCER-PATIENTS TREATED WITH RECOMBINANT IL-2
    SCHARENBERG, JGM
    STAM, AGM
    VONBLOMBERG, BME
    ROEST, GJ
    PALMER, PA
    FRANKS, CR
    MEIJER, CJLM
    SCHEPER, RJ
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (12) : 1804 - 1809
  • [38] Immunotherapy targeting IL-2 and IL-15 cytokine receptors
    Waldmann, Thomas
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [39] Cytokine profile in the saliva of patients with active psoriasis revealed significant upregulation of TNF-α, IFN-γ, IL-2 and downregulation of IL-10
    Sharma, Ravi Kant
    Sharma, Manu Rashmi
    Mahendra, Aneet
    Sood, Shaveta
    Kumar, Aman
    Sharma, Anil Kumar
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (06)
  • [40] Evaluation of the circulating levels of IL-2 and IL-33 in patients with breast cancer: influences of the tumor stages and cytokine gene polymorphisms
    Jafarzadeh, Abdollah
    Minaee, Kayhan
    Farsinejad, Ali-Reza
    Nemati, Maryam
    Khosravimashizi, Arezu
    Daneshvar, Hamid
    Mohammadi, Mohammad Mehdi
    Sheikhi, Abdolkarim
    Ghaderi, Abbas
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2015, 18 (12) : 1189 - 1198